Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 28;2(4):otaa061. doi: 10.1093/crocol/otaa061

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

FIGURE 2. — Clinical remission at weeks 8, 16, 24, and 52 in 63 patients with active disease. (A) Percentages of patients achieving clinical remission out of 40 clinically moderate to severely active CD patients treated with UST at weeks 8, 16, 24, and 52. (B) The clinical remission rate at week 52 was 75% in anti-TNF-naive patients and 26.7% in anti-TNF-exposed patients. (C) The clinical remission rate at week 52 was 38.9% in patients receiving UST monotherapy and 25.0% in those receiving combination therapy with immunomodulators.